论文部分内容阅读
目的观察尼莫地平治疗高血压脑出血的临床疗效。方法选择解放军171医院2013年收治的高血压脑出血患者68例,随机分成对照组和试验组,各34例。两组患者均给予内科常规治疗,试验组患者在此基础上给予尼莫地平治疗,疗程为21 d。比较两组患者入院第1天、第4天、第10天、第14天脑水肿和血肿量,观察治疗期间两组患者不良反应发生情况。结果入院第1天两组患者脑水肿和血肿量比较,差异无统计学意义(P>0.05);入院第4天、第10天及第14天,试验组患者脑水肿和血肿量均少于对照组(P<0.05)。试验组患者不良反应发生率为41.2%,低于对照组的76.5%(P<0.05)。结论尼莫地平可促进高血压脑出血患者血肿吸收,减轻脑水肿程度,且安全性高。
Objective To observe the clinical efficacy of nimodipine in the treatment of hypertensive intracerebral hemorrhage. Methods Sixty-eight patients with hypertensive intracerebral hemorrhage admitted to the 171 Hospital of PLA in 2013 were randomly divided into control group and trial group, with 34 cases in each group. Two groups of patients were given conventional medical treatment, patients in the experimental group on the basis of nimodipine treatment, the course of treatment was 21 d. The cerebral edema and hematoma volume were compared between the two groups on the first day, the fourth day, the tenth day and the fourteenth day after admission. The incidence of adverse reactions in the two groups was observed during the treatment. Results There was no significant difference in brain edema and hematoma volume between the two groups on the first day after admission (P> 0.05). On the 4th, 10th and 14th day after admission, the brain edema and hematoma in the experimental group were less than Control group (P <0.05). The incidence of adverse reactions in the trial group was 41.2%, which was lower than 76.5% in the control group (P <0.05). Conclusion Nimodipine can promote the hematoma absorption in patients with hypertensive intracerebral hemorrhage, reduce the degree of cerebral edema and have high safety.